TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7016300

Group type: EXPERIMENTAL
Intervention: BCG treatment (120 mg intravesically and 5 mg percutaneously, six weekly administrations)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 51
Study: 30712725

Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 27683798

Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Increased dosing frequency from every 8 weeks to every 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 100
Study: 26072416

Group type: EXPERIMENTAL
Intervention: Pexa-Vec (JX-594) administered by intratumoral injection at a dose of 1 × 10(8) pfu
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pexa-Vec (JX-594) administered by intratumoral injection at a dose of 1 × 10(9) pfu
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24421886

Group type: EXPERIMENTAL
Intervention: BPZE1 (10³, 10⁵, or 10⁷ CFU)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (diluent)
Number of subjects: 36
Study: 22021066

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination with cyclophosphamide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dendritic cell vaccination without cyclophosphamide (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 11
Study: 20004781

Group type: EXPERIMENTAL
Intervention: BI 1744 (2 microg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BI 1744 (5 microg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BI 1744 (10 microg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: BI 1744 (20 microg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16613765

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCD) - 4200 kcal/24 h
Number of subjects: 32

Group type: COMPARATOR
Intervention: Habitual diet (HD) - 3200 kcal/24 h
Number of subjects: 32
Study: 12663290

Group type: EXPERIMENTAL
Intervention: Black tea (1250 mL/d, 5 cups each containing 2 g tea leaves in 250 mL boiled water)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hot water (1250 mL/d)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 22
Study: 10859453

Group type: EXPERIMENTAL
Intervention: Morphine plus MLT (20 mg/day orally in the evening)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine plus MLT
Number of subjects: 30
Study: 8889853

Group type: EXPERIMENTAL
Intervention: Noncemented THA
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cemented THA
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control sides (not undergoing THA)
Number of subjects: 53
Study: 10895734

Group type: EXPERIMENTAL
Intervention: Patient age 84 years
Number of subjects: 159

Group type: COMPARATOR
Intervention: Patient age 65 years
Number of subjects: 159

Group type: COMPARATOR
Intervention: Patient age 44 years
Number of subjects: 159
Study: 6360110

Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment five times a day in combination with alpha-interferon (30 million IU/mL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 3% acyclovir ointment five times a day
Number of subjects: 59
Study: 31672145

Group type: EXPERIMENTAL
Intervention: ACTION Respecting Choices (RC) ACP conversation
Number of subjects: 39
Study: 30327351

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27923864

Group type: EXPERIMENTAL
Intervention: Extended Need Support (ENS; eight contacts over 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harm Reduction (HR; eight contacts over 12 months with medication use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive Treatment (IT; six contacts over 6 months)
Number of subjects: 0
Study: 24042068

Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Non-surgical rehabilitation
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 106
Study: 22908692

Group type: EXPERIMENTAL
Intervention: FeSO₄
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of FeSO₄ and NaFeEDTA
Number of subjects: 29

Group type: COMPARATOR
Intervention: FeSO₄ (control in study 2)
Number of subjects: 29
Study: 20524974

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 1,000 mg IM at baseline, and after 6 and 18 weeks)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 184
Study: 17907030

Group type: EXPERIMENTAL
Intervention: Over-the-head (OTH) CPR
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard CPR with bag-valve-mask (BVM) ventilation
Number of subjects: 8
Study: 15531561

Group type: EXPERIMENTAL
Intervention: Hypoxic challenge (15% O(2), 85% N(2)) during functional MRI assessment.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hypoxic challenge (15% O(2), 85% N(2)) in CCHS patients.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hypoxic challenge (15% O(2), 85% N(2)) in controls.
Number of subjects: 14
Study: 12002960

Group type: EXPERIMENTAL
Intervention: Computer-adaptive test with manipulated difficulty of initial and subsequent items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback consistent with perceptions of performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minor changes to the design of an adaptive test
Number of subjects: 0
Study: 10426171

Group type: EXPERIMENTAL
Intervention: SGA
Number of subjects: 32

Group type: COMPARATOR
Intervention: Preterm
Number of subjects: 32
Study: 7823995

Group type: EXPERIMENTAL
Intervention: Once-daily trial of spontaneous breathing
Number of subjects: 546

Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation
Number of subjects: 546

Group type: COMPARATOR
Intervention: Pressure-support ventilation
Number of subjects: 546

Group type: COMPARATOR
Intervention: Intermittent trials of spontaneous breathing
Number of subjects: 546
Study: 2079566

Group type: EXPERIMENTAL
Intervention: Interferon 5 million units per day with prednisone withdrawal (Group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon 1 million units (Group C)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Placebo followed by interferon 5 million units (Group B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Interferon 5 million units with prednisone withdrawal (Group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Untreated controls (Group D)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All treatment responders (Groups A, B, C)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Non-responders from groups A and B
Number of subjects: 57
Study: 90270

Group type: EXPERIMENTAL
Intervention: 100 mg BAY g 5421 before a 50 g sucrose meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isotopic method for gastric emptying
Number of subjects: 10
Study: 31863251

Group type: EXPERIMENTAL
Intervention: Endocardial LAA isolation during RFA for AF
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: LAA exclusion with LARIAT device followed by RFA for AF
Number of subjects: 182
Study: 31615549

Group type: EXPERIMENTAL
Intervention: myTAPS screening tool
Number of subjects: 2000
Study: 29354671

Group type: EXPERIMENTAL
Intervention: Tiotropium HandiHaler®
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 25712847

Group type: EXPERIMENTAL
Intervention: Chest tube removal on the 2nd day after operation (Experimental Group - EG)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Chest tube removal when drainage volume <100 ml/day (Control Group - CG)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Open thoracic lobectomy (OG)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: All groups (EG, CG, OG)
Number of subjects: 154
Study: 22310245

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at constant intensity
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at gradually increasing intensity
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both conditions (constant and gradually increasing intensity)
Number of subjects: 11
Study: 21692283

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 91

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 91

Group type: COMPARATOR
Intervention: Combined therapy of electroacupuncture and acupoint injection
Number of subjects: 91
Study: 20218480

Group type: COMPARATOR
Intervention: Dynamic exercise rehabilitation programme (CER)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Upper body strength training programme (UBST)
Number of subjects: 30
Study: 16462284

Group type: EXPERIMENTAL
Intervention: Pocket AOM card
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total AOM card severity
Number of subjects: 0
Study: 12707868

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 116

Group type: COMPARATOR
Intervention: Modified Burch colposuspension
Number of subjects: 116
Study: 10731289

Group type: EXPERIMENTAL
Intervention: Enoxaparin and abciximab administration during percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abciximab administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study: 8613615

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided focal ablation technique (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Linear ablation technique (Group II)
Number of subjects: 60
Study: 1571752

Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Clomipramine (100-200 mg/day)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 129

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 129
Study: 3883503

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 40 mg orally, four times daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: Tamoxifen 10 mg orally twice daily
Number of subjects: 124

Group type: COMPARATOR
Intervention: Crossover from megestrol acetate to tamoxifen
Number of subjects: 124

Group type: COMPARATOR
Intervention: Crossover from tamoxifen to megestrol acetate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 124
Study: 29767281

Group type: EXPERIMENTAL
Intervention: Acceptance of gender inequitable norms
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Acceptance of IPV
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Higher self-esteem
Number of subjects: 919
Study: 29874228

Group type: EXPERIMENTAL
Intervention: 4-site/1-week regimen (PCECV)
Number of subjects: 885

Group type: COMPARATOR
Intervention: 2-site/TRC regimen (PCECV)
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: 4-site/1-week regimen with HRIG
Number of subjects: 885

Group type: COMPARATOR
Intervention: 2-site/TRC regimen with HRIG
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: 4-site/1-week regimen
Number of subjects: 885

Group type: COMPARATOR
Intervention: 2-site/TRC regimen
Number of subjects: 885
Study: 25486294

Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation (3.4 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL; 5 g maltodextrin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (BA and PL)
Number of subjects: 16
Study: 24571184

Group type: EXPERIMENTAL
Intervention: Vibration Training Group (VTG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Training Group (CTG)
Number of subjects: 20
Study: 22963388

Group type: EXPERIMENTAL
Intervention: Oriental Medicine Music Therapy (OMMT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Music Therapy (CMT)
Number of subjects: 48
Study: 21054464

Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, and Clarithromycin (OAC)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Rabeprazole, Amoxicillin, and Clarithromycin (RAC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: IL-1RN and IL-1B genotype groups
Number of subjects: 240
Study: 18020933

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Other psychosocial interventions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nonpsychologist-led interventions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Samples consisting of only BC patients
Number of subjects: 56
Study: 16344384

Group type: EXPERIMENTAL
Intervention: Slow-release (SR) TAXUS stents
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Moderate-release (MR) TAXUS stents
Number of subjects: 161

Group type: COMPARATOR
Intervention: Bare-metal control stents (BMS)
Number of subjects: 161
Study: 12160664

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (up to 600 mg daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 11811503

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Osseous surgery (OS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modified Widman (MW)
Number of subjects: 16
Study: 9622282

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg o.d.)
Number of subjects: 15
Study: 7933456

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Moduretic
Number of subjects: 9

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 9
Study: 3063782

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg)
Number of subjects: 14
Study: 29621293

Group type: EXPERIMENTAL
Intervention: Apomorphine (1.5 mg subcutaneous injection)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 27164988

Group type: EXPERIMENTAL
Intervention: Transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy (NAC) for AEG patients
Number of subjects: 83

Group type: COMPARATOR
Intervention: D2 gastrectomy after neoadjuvant chemotherapy (NAC) for non-AEG patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Transhiatal approach and D2 total gastrectomy after NAC
Number of subjects: 83

Group type: COMPARATOR
Intervention: D2 gastrectomy after NAC
Number of subjects: 83
Study: 26222764

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST) including neoadjuvant paclitaxel ± carboplatin ± bevacizumab followed by doxorubicin plus cyclophosphamide ± bevacizumab
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST)
Number of subjects: 404
Study: 24007766

Group type: EXPERIMENTAL
Intervention: Person-centred education including device technique
Number of subjects: 114

Group type: COMPARATOR
Intervention: Written information-only education
Number of subjects: 114
Study: 21048092

Group type: EXPERIMENTAL
Intervention: Dopexamine (0.5 μg · kg(‐1) · min(‐1))
Number of subjects: 124

Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 124
Study: 19032126

Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma (81.9% of patients)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Atopy detected in patients
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Early onset of asthma
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Atopic symptoms (allergic rhinitis)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Atopic symptoms (rhinosinusitis)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Number of medications
Number of subjects: 1009
Study: 17010742

Group type: EXPERIMENTAL
Intervention: 1 mg/L methoxsalen
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 5 mg/L methoxsalen
Number of subjects: 46
Study: 14740594

Group type: EXPERIMENTAL
Intervention: 5 mg bupivacaine 0.1% mixed with 20 micrograms fentanyl
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5 mg bupivacaine 0.1%
Number of subjects: 80
Study: 10811540

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8623956

Group type: EXPERIMENTAL
Intervention: 5.0% sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5.0% isoflurane
Number of subjects: 50
Study: 1441877

Group type: EXPERIMENTAL
Intervention: 20 ml of 2.2% lidocaine hydrocarbonate with 5 micrograms.ml‐1 epinephrine (Group CO2 = 13 patients)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 20 ml of 2% lidocaine hydrochloride with 5 micrograms.ml‐1 epinephrine (HCl group)
Number of subjects: 26
Study: 30092657

Group type: EXPERIMENTAL
Intervention: Make the Connection (MTC) parenting programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Time (regardless of programme participation)
Number of subjects: 180
Study: 27515885

Group type: EXPERIMENTAL
Intervention: Kuan-Sin-Yin (KSY) herbal decoction, 100 mL daily for 6 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo herbal decoction, 100 mL daily for 6 weeks
Number of subjects: 70
Study: 23489742

Group type: EXPERIMENTAL
Intervention: nTMS
Number of subjects: 18

Group type: COMPARATOR
Intervention: cTMS
Number of subjects: 18
Study: 23775525

Group type: EXPERIMENTAL
Intervention: Caloric-restricted diet
Number of subjects: 19
Study: 21169172

Group type: EXPERIMENTAL
Intervention: Web-based brief alcohol intervention without normative feedback
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Web-based brief alcohol intervention with normative feedback
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 575
Study: 19105251

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17019893

Group type: EXPERIMENTAL
Intervention: Number of nodes of placental surface arteries
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Placental weights
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Topological factor (number of nodes)
Number of subjects: 26
Study: 12911589

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 217
Study: 11286466

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 83
Study: 9296940

Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin 1.2 g
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 8282140

Group type: EXPERIMENTAL
Intervention: Estriol (8 mg/day first week, 4 mg/day second and third week, 2 mg/day fourth week)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Estriol
Number of subjects: 62
Study: 3735179

Group type: EXPERIMENTAL
Intervention: Exercise program (moderate intensity, nonsocial)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 14
Study: 29653270

Group type: EXPERIMENTAL
Intervention: Early decompressive craniotomy (within 6 hours of presentation)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed decompressive craniotomy (followed until deterioration of consciousness)
Number of subjects: 46
Study: 27903566

Group type: EXPERIMENTAL
Intervention: General practitioners treating homeless people (HP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Perceived difficulties in treating HP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lack of medical information
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patient's compliance
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Loneliness in practice
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Time required for the doctor
Number of subjects: 150
Study: 24885549

Group type: EXPERIMENTAL
Intervention: Baseline assessment of spinal pain prevalence
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Follow-up assessment of spinal pain prevalence
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Baseline assessment of frequent pain
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Follow-up assessment of frequent pain
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Two-year incidence of spinal pain
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Progression of pain over two years
Number of subjects: 1348
Study: 22726470

Group type: EXPERIMENTAL
Intervention: Endoscopist training (two 1-hour training sessions)
Number of subjects: 1231
Study: 20406589

Group type: EXPERIMENTAL
Intervention: Coseasonal therapy with 5000 AU/week for 6 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Precoseasonal therapy with 3000 AU/week for 10 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 33
Study: 19731175

Group type: EXPERIMENTAL
Intervention: With hand grip (WG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Without hand grip (WOHG)
Number of subjects: 15
Study: 15708385

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg, two doses six months apart)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 702